Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) is scheduled to be announcing its earnings results after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Puma Biotechnology has set its Q1 2024 guidance at EPS and its FY 2024 guidance at EPS.Investors interested in listening to the company’s conference call can do so using this link.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.07). Puma Biotechnology had a return on equity of 58.21% and a net margin of 9.16%. The firm had revenue of $72.20 million for the quarter, compared to the consensus estimate of $73.22 million. On average, analysts expect Puma Biotechnology to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Puma Biotechnology Trading Down 5.8 %

Shares of NASDAQ:PBYI opened at $4.83 on Thursday. Puma Biotechnology has a 12-month low of $2.13 and a 12-month high of $7.73. The stock has a market cap of $232.84 million, a PE ratio of 10.50, a P/E/G ratio of 2.94 and a beta of 1.28. The business has a 50 day moving average of $5.64 and a 200-day moving average of $4.55. The company has a quick ratio of 1.50, a current ratio of 1.57 and a debt-to-equity ratio of 1.23.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on PBYI shares. HC Wainwright reduced their price objective on Puma Biotechnology from $8.00 to $7.00 and set a “buy” rating for the company in a report on Friday, March 1st. StockNews.com downgraded shares of Puma Biotechnology from a “buy” rating to a “hold” rating in a research report on Wednesday, April 10th.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.